PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
2015 · New England Journal of Medicine · 9,230 citations
https://doi.org/10.1056/nejmoa1500596
T
Todd S. Crocenzi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
105
Papers
26.1K
Citations
31
h-index
46
i10-index
Todd S. Crocenzi is an academic researcher. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & Immunotherapy and Immune Responses. The author has an h-index of 31, co-authored 90 publications.
ORCID: 0000-0001-8762-1990Papers by this author
worksMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
2017 · Science · 6,510 citations
https://doi.org/10.1126/science.aan6733
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
2015 · Journal of Clinical Oncology · 588 citations
https://doi.org/10.1200/jco.2014.57.4244
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
2019 · Clinical Cancer Research · 250 citations
https://doi.org/10.1158/1078-0432.ccr-18-2992
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking
2020 · Nature Communications · 204 citations
https://doi.org/10.1038/s41467-020-15404-8
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
2020 · Clinical Cancer Research · 148 citations
https://doi.org/10.1158/1078-0432.ccr-19-3978
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat